Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1096P (RNA, U6 small nuclear 1096, pseudogene) is a pseudogene derived from the U6 small nuclear RNA (snRNA) family, annotated as a non-coding RNA and classified as a pseudogene in the human genome[2]. U6 snRNA itself is an essential component of the spliceosome, the molecular machinery responsible for splicing pre-mRNA in eukaryotes[1][3][5]. However, pseudogenes like RNU6-1096P do not encode functional RNA or protein products and typically arise through gene duplication or retrotransposition events. While some RNA pseudogenes have regulatory roles through RNA interference or competing for microRNAs, there is no direct evidence or functional characterization for RNU6-1096P in cellular or disease contexts[4][2]. Thus, RNU6-1096P is not considered a therapeutic target and there is nothing to suggest it is directly involved in known biological pathways or disease processes.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1096, pseudogene (RNU6-1096P).